Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Titan Pharmaceuticals, Inc. (TTNP)

0.99   0.01 (1.02%) 02-03 15:11
Open: 1.04 Pre. Close: 0.98
High: 1.04 Low: 0.97
Volume: 56,689 Market Cap: 14(M)

Technical analysis

as of: 2023-02-03 2:50:56 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.27     One year: 1.48
Support: Support1: 0.86    Support2: 0.73
Resistance: Resistance1: 1.09    Resistance2: 1.27
Pivot: 0.96
Moving Average: MA(5): 0.99     MA(20): 0.95
MA(100): 0.97     MA(250): 0.96
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 53.6     %D(3): 61.7
RSI: RSI(14): 54.2
52-week: High: 1.59  Low: 0.34
Average Vol(K): 3-Month: 43 (K)  10-Days: 59 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TTNP ] has closed below upper band by 45.7%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.05 - 1.06 1.06 - 1.06
Low: 0.94 - 0.94 0.94 - 0.95
Close: 0.96 - 0.97 0.97 - 0.98

Company Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Headline News

Tue, 31 Jan 2023
Premarket Mover: Titan Pharmaceuticals, Inc. common stock (TTNP) Up 7.07% - InvestorsObserver

Fri, 27 Jan 2023
Theriva Biologics, Research Frontiers And 1 Other Penny Stock ... - UK

Thu, 15 Dec 2022
Titan Pharmaceuticals Provides Shareholder Update - BioSpace

Mon, 12 Dec 2022
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing ... - GlobeNewswire

Thu, 28 Jul 2022
Titan Pharmaceuticals Inc (NASDAQ: TTNP) Receives FDA ... - BP Journal

Tue, 05 Jul 2022
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving - Penny Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 10 (M)
% Held by Insiders 1.088e+007 (%)
% Held by Institutions 25.6 (%)
Shares Short 428 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -9.17e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 267.2
Return on Equity (ttm) -59.2
Qtrly Rev. Growth 740000
Gross Profit (p.s.) -58.68
Sales Per Share -116.13
EBITDA (p.s.) -3.86726e+006
Qtrly Earnings Growth -4.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 2.19

Stock Dividends

Dividend 0
Forward Dividend 271610
Dividend Yield 0%
Dividend Pay Date 2020-11-30
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.